Skip to main content
Clinical Trials/NCT02033486
NCT02033486
Unknown
Not Applicable

Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)

Massachusetts General Hospital1 site in 1 country375 target enrollmentMarch 2014
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Massachusetts General Hospital
Enrollment
375
Locations
1
Primary Endpoint
Area under the curve for distinguishing benign vs malignant lesions
Last Updated
7 years ago

Overview

Brief Summary

Screening for breast cancer improves early detection of aggressive cancers and has been shown to reduce breast cancer related mortality. Currently, mammography is the most effective way of detecting early stage, non palpable breast cancers. However, mammography only reveals the breast structure, and cannot say much about the breast physiological state. We propose Tomographic Optical Breast Imaging (TOBI) as an inexpensive, patient friendly technique that is non-invasive and does not use non-ionizing radiation. TOBI uses near infrared light and by measuring how such light passes through the breast, images of blood volume and hemoglobin oxygenation can be obtained. In this study, TOBI is combined with digital breast tomosynthesis (DBT, a form of 3D mammography) and our hypothesis is that the TOBI-DBT combined images can be used to diagnose breast cancer with significantly improved sensitivity and specificity compared to DBT alone.

Registry
clinicaltrials.gov
Start Date
March 2014
End Date
March 2021
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mansi A Saksena

Assistant Professor at Massachusetts General Hospital

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Any adult female volunteers of any race or ethnic background, between the ages of 30 to 80, either
  • scheduled for a clinically indicated diagnostic mammogram or percutaneous biopsy.
  • presenting for breast cancer treatment

Exclusion Criteria

  • Under 30 years old or over 80 years old
  • Is pregnant or thinks she may become pregnant.
  • Open wounds on breast
  • Breast implants
  • Any condition that impairs the ability to give informed consent

Outcomes

Primary Outcomes

Area under the curve for distinguishing benign vs malignant lesions

Time Frame: 5 years

We will compare optical-DBT vs DBT in terms of diagnosis specificity within the diagnostic population. We will base our analysis on total hemoglobin contrast which has been shown before by our group to be significantly different between malignant and benign lesions. By setting a threshold total hemoglobin ratio and comparing with the biopsy results, we can obtain a point on the receiver operating characteristic (ROC) for the selected parameter. By sliding the threshold over all possible values, we will render the full ROC curve. The area under the curve (AUC) will be calculated to compare with that of DBT.

Study Sites (1)

Loading locations...

Similar Trials